Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Hsbc Holdings PLC

Hsbc Holdings PLC grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 40.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 578,120 shares of the medical equipment provider’s stock after buying an additional 166,172 shares during the quarter. Hsbc Holdings PLC owned 0.28% of Zimmer Biomet worth $62,653,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. OLD Point Trust & Financial Services N A purchased a new stake in Zimmer Biomet during the fourth quarter worth about $26,000. Ables Iannone Moore & Associates Inc. purchased a new stake in Zimmer Biomet during the 4th quarter worth approximately $30,000. Crewe Advisors LLC acquired a new stake in Zimmer Biomet during the 1st quarter worth approximately $31,000. Family Firm Inc. purchased a new position in Zimmer Biomet in the 2nd quarter valued at approximately $33,000. Finally, J.Safra Asset Management Corp grew its stake in shares of Zimmer Biomet by 712.1% in the first quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 235 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 0.0 %

ZBH opened at $106.32 on Friday. The company has a quick ratio of 0.63, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. Zimmer Biomet Holdings, Inc. has a 52 week low of $102.00 and a 52 week high of $133.90. The business’s 50 day moving average is $109.88 and its two-hundred day moving average is $115.65. The firm has a market cap of $21.65 billion, a price-to-earnings ratio of 23.01, a price-to-earnings-growth ratio of 1.96 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 EPS for the quarter, beating the consensus estimate of $1.99 by $0.02. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The firm had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.94 billion. During the same quarter in the prior year, the firm earned $1.82 EPS. Zimmer Biomet’s revenue for the quarter was up 3.9% on a year-over-year basis. On average, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.02 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.90%. The ex-dividend date is Monday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Evercore ISI reiterated an “in-line” rating and issued a $113.00 target price on shares of Zimmer Biomet in a report on Thursday, September 5th. Royal Bank of Canada lowered their price objective on Zimmer Biomet from $140.00 to $130.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Barclays cut their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating on the stock in a research note on Friday, May 31st. Truist Financial reiterated a “hold” rating and set a $112.00 price target (down previously from $117.00) on shares of Zimmer Biomet in a report on Friday, September 13th. Finally, UBS Group reduced their price objective on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a report on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $125.17.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.